John Goldman Award

ESH international John Goldman Research Award 2026

The European School of Haematology (ESH) is proud to announce
the 7th ESH International John Goldman Research Award
The recipient of this annual award will receive a total of 80K€ to finance or co-finance a research project with a focus on MRD in CML and MPN related diseases.  

80K€

Total funding

MRD in CML & MPN related diseases

Research focus

2 years

Maximum duration

Young & established researchers

International scope

The 7th ESH International John Goldman
Research Award is presented to
Dr Mariela Cortés-Lopéz

Principal Investigator:
Helmholtz Munich (ICB) & Dr. von Haunersches Kinderspital (LMU), Munich, Germany

For her two-year project on:

"Splicing-driven telomere vulnerability as a biomarker and therapeutic target in myelofibrosis"

‍

“I am honoured to receive the John Goldman Award. As a new principal investigator, this support will be a major boost as I build my lab and venture into new territory, bringing together machine learning and technology development to uncover new disease mechanisms and open up better ways to understand and, eventually, treat myelofibrosis.”

THE ESH INTERNATIONAL JOHN GOLDMAN AWARD CEREMONY 2026 TOOK PLACE DURING THE ESH-iCMLf 28th ANNUAL JOHN GOLDMAN CONFERENCE ON CHRONIC MYELOID LEUKEMIA: BIOLOGY AND THERAPY, ON OCTOBER 2-4, 2026, IN GOTHENBURG, SWEDEN.

Stay tuned for the next Award call for applications!
‍
For further information please contact camille.frank(@)u-paris.fr with copy to clotilde.magistry(@)u-paris.fr
‍

CALL FOR APPLICATION IS NOW CLOSED

‍The research project start date will be November 1st, 2026 and will have a maximum duration of two years. The Research Project must:

  • Aim to develop methods to early and reliably identify CML and MPN patients(or related diseases) resistant to first line therapies
  • And/or evaluate new treatment options for CML and MPN patients (or related diseases)

Stay tuned for the announcement of the awardee.

The ESH International John Goldman Award Ceremony 2026 will take place during the ESH-iCMLf 28th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy, on October 2-4, 2026, in Gothenburg, Sweden.
‍

CALL FOR APPLICATIONS

The research project start date will be November 1st, 2026 and will have a maximum duration of two years. The Research Project must:

  • Aim to develop methods to early and reliably identify CML and MPN patients(or related diseases) resistant to first line therapies
  • And/or evaluate new treatment options for CML and MPN patients (or related diseases)

DEADLINE FOR SUBMISSION: JUNE 10, 2026

Download and complete the call for application  →

* Pending ARS approval (under review - grant may not be provided without ARS approval)

Please send your application by email to:
camille.frank@u-paris.fr with copy to clotilde.magistry@u-paris.fr

All submitted applications will be peer reviewed independently by a committee of academic researchers appointed by ESH.

Previous ESH John Goldman Research Awardees

Dr Stein Erik Gullaksen

Dept. of Medicine, Haukeland University Hospital, Bergen, Norway
“I am honored and grateful to receive the John Goldman Research Award for our work on single-cell precision medicine in CML. Our project aims to develop cutting-edge mass cytometry assays that can identify treatment-resistant patients within hours of starting TKI therapy, potentially transforming how we approach personalized treatment decisions in CML. This prestigious recognition from the European School of Haematology will provide crucial support to advance our goal of developing rapid, clinically implementable tools that can predict treatment response and ultimately improve patient outcomes through early, individualized therapy optimization.”

Dr. Carmen Fava

Dept. of Clinical and Biological Science
University of Turin, Italy
“Receiving the John Goldman Award is an extraordinary achievement that fills me with pride, gratitude and motivation. I definitely feel a sense of responsibility in representing the values and standards of this award. The prestige and resources associated with this grant will help me gain new skills and experience.This award will significantly support my project and career development by enhancing my visibility, providing additional resources and opening up new opportunities for collaboration and advancement.This recognition strengthens my confidence, also encouraging me to take on more ambitious projects.”
JOHN GOLDMAN 2024

Dr. Naranie Shanmuganathan

Royal Adelaide Hospital, Adelaide, Australia
“My project will hopefully help pave the path for genomic interrogation of CML patients at diagnosis so for the merits of the project to be recognized and awarded the John Goldman prize is a huge honour.This successful completion of this work will be beyond helpful in aidingmy future research career in haematology.”
JOHN GOLDMAN 2021

Dr. Emmanuelle Clappier

Dept. of Haematology, Saint-Louis Hospital, Paris, France
“I am very honored and grateful to receive the 2021 John Goldman Research Award. Our project on Ph+ ALL stems from previous observations of presence of residual, non-lymphoblastic, BCR-ABL1+ cells in patients in continuous complete remission, challenging the significance of BCR-ABL1-based MRD in Ph+ ALL. This support from the European School of Hematology will allow us to develop single-cell omics approaches in order to decipher the clonal architecture of Ph+ ALL, which will impact on therapeutic management of these patients.”
JOHN GOLDMAN 2021

Dr. Vaidehi Krishnan

Laboratory of Hematological Malignancies, DUKE-NUS, Singapore
“I am honoured and thankful to be chosen as the recipient of the John Goldman Research Award this year.  Our project aims to interrogate diagnostic CML bone marrow samples using the latest single-cell approaches, and identify patients who will have durable treatment free responses. By integrating the results of our analyses with established clinical workflows, we hope to develop a test that can reliably predict the outcome of TKI discontinuation.  This prestigious award from the European School of Haematology offers us the opportunity to leverage cutting-edge technologies toward our long-term goal of developing curative approaches for patients with CML.”
JOHN GOLDMAN 2021

Dr. Ilaria Pagani

Leukaemia Research Group, Cancer Program, SAHMRI, Adelaide, Australia
“It is an honour and a pleasure to be the first John Goldman Research Prize Awardee. Receiving funding support from the European School of Haematology (ESH) is a privilege. It represents a critical step in my career towards becoming an independent investigator and provides the opportunity to build new collaborations. My project aims to identify bioassays that can be integrated with clinical data in a machine learning system to develop a personalized predictive model for treatment free remission (TFR). I expect it will bring novel insights into the biology of TFR, opening new horizons toward the discovery of targeted therapies and improving TFR patient outcome.”
JOHN GOLDMAN 2021
ESH extends sincere thanks to the Award reviewers:
Jorge Cortes (Augusta, USA)
Hervé Dombret (Paris, France)
Michael Hallek (Cologne, Germany)
Andreas Hochhaus (Jena, Germany)
Daniela S. Krause (Frankfurt, Germany)
Andrew Rawstron (Leeds, UK)
Alessandro Vannucchi (Florence, Italy)

We invite you to watch the panel discussion video on the 1st International John Goldman Research Award on Treatment Free Remission, with:

  • Hervé Dombret, ESH President, Saint-Louis Research Institute, Saint-Louis Hospital, Paris (Moderator),
  • Daniela Krause, ESH Scientific Committee member, Georg-Speyer-Haus and Goethe University Frankfurt (Panelist),
  • François-Xavier Mahon, ESH Scientific Committee past member, Institut Bergonié, Bordeaux (Panelist),
  • Ilaria Pagani, 1st John Goldman Awardee, South Australian Health and Medical Research Institute, Adelaide (Panelist),
  • Ana Rita Ferreira, Medical Director CML, Novartis Europe (Panelist)

Advancing haematology through international leading-edge disease- focused conferences.

Explore a portfolio of leading-edge scientific, translational research and clinically oriented meetings, designed to foster scientific exchange, practical insight, education and collaboration across clinical and research fields.
Explore all conferences